These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11880208)

  • 1. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
    van Herpen CM; De Mulder PH
    Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
    van Herpen CM; de Mulder PH
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma.
    Lissoni P; Barni S; Ardizzoia A; Andres M; Scardino E; Cardellini P; Della Bitta R; Tancini G
    Tumori; 1993 Dec; 79(6):397-400. PubMed ID: 8171738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha.
    Canobbio L; Rubagotti A; Miglietta L; Cannata D; Curotto A; Amoroso D; Boccardo F
    J Cancer Res Clin Oncol; 1995; 121(12):753-6. PubMed ID: 7499447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors of immunotherapy in metastatic renal cell carcinoma.
    Padrik P
    Med Oncol; 2003; 20(4):325-34. PubMed ID: 14716028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
    Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
    Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
    Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapeutic treatment for metastatic renal carcinoma].
    Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
    Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of immunotherapy in metastatic cancer of the kidney].
    Thiounn N
    J Urol (Paris); 1994; 100(5):231-7. PubMed ID: 7730669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.